Improving Acalabrutinib Delivery with Solid Lipid Nanoparticles
Author Information
Author(s): Swagata Sinha, Punna Rao Ravi, Makarand Somvanshi, Rashmi S. R.
Primary Institution: Birla Institute of Technology and Science, Pilani
Hypothesis
Can solid lipid nanoparticles enhance the oral bioavailability of acalabrutinib in chronic lymphocytic leukaemia?
Conclusion
The study found that acalabrutinib-loaded solid lipid nanoparticles significantly increased oral bioavailability and drug distribution to the spleen compared to conventional formulations.
Supporting Evidence
- The optimized ACP-SLNs had a particle size of 234.7–257.5 nm and loading efficiency of 18.70 ± 1.78%.
- ACP-SLNs resulted in a 2.29-fold increase in oral bioavailability compared to the bulk drug suspension.
- More than 90% of the drug was released at pH 4.5, 6.8, and 7.4 after 8, 16, and 24 hours, respectively.
- The freeze-dried product was stable when stored at 5 °C for over 6 months.
- Administration of cycloheximide resulted in a 46.01% decrease in overall absorption of ACP-SLNs.
Takeaway
Researchers made tiny particles to help a cancer drug work better in the body, and it worked really well!
Methodology
The study involved formulating acalabrutinib into solid lipid nanoparticles using a solvent-free hot emulsification technique followed by double sonication.
Potential Biases
Potential bias in the selection of animal models and the formulation process.
Limitations
The study primarily focused on animal models, which may not fully represent human responses.
Participant Demographics
Male Wistar rats weighing approximately 220–250 g were used in the study.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website